David Colleran compensation by year
Anika Therapeutics Summary Compensation Table · all 6 fiscal years held| Component | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Salary | $344,077 | $432,400 | $449,700 | $469,900 | $481,996 | $486,424 |
| Bonus | $143,931 | $194,597 | $202,365 | $202,194 | $177,302 | $219,000 |
| Stock awards | $645,900 | $375,598 | $588,033 | $441,189 | $492,137 | $889,624 |
| Option awards | $553,445 | $375,853 | $399,061 | $412,475 | $491,346 | $0 |
| Non-equity incentive | $0 | $0 | $0 | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $18,263 | $22,064 | $12,476 | $24,756 | $25,806 | $19,157 |
| Total | $1,705,616 | $1,400,513 | $1,651,635 | $1,550,514 | $1,668,587 | $1,614,205 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Anika Therapeutics, Inc. DEF 14A filed April 28, 2026, accession 0001140361-26-017488, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Anika Therapeutics, Inc. filed document, accession 0001140361-26-017488. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 28,165 | $270,666 | — |
| RSU | 15,625 | $150,156 | — |
| RSU | 14,082 | $135,328 | — |
| RSU | 13,669 | $131,359 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in Anika Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Anika Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Cheryl Blanchard | Executive Chair; Former President and Chief Executive Officer | $4,887,318 |
| Stephen Griffin | President and Chief Executive Officer; Former EVP, Chief Financial Officer and Chief Operating Officer | $2,033,370 |
| David Colleran · this page | Executive Vice President, General Counsel and Secretary | $1,614,205 |
| Anne Nunes | Former Senior Vice President, Chief Operations Officer | $946,571 |
| Ian McLeod | Senior Vice President, Chief Accounting Officer and Treasurer | $765,544 |
David Colleran's compensation dossier, Anika Therapeutics
You have read David Colleran's totals and holdings. The dossier adds each equity grant Anika Therapeutics disclosed for David Colleran and Anika Therapeutics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Anika Therapeutics compensation record
free company briefThis page is one person within Anika Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Anika Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Anika Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Anika Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order ANIK
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.